[Chinese expert consensus on the diagnosis and treatment of plasma cell leukemia (2025)].

Plasma cell leukemia (PCL) is a rare and highly aggressive form of plasma cell dyscrasia, distinguished by its rapid clinical course and dismal prognosis. This guideline is intended to offer clinicians evidence-based, comprehensive recommendations encompassing diagnostic criteria, risk stratification, therapeutic approaches-including frontline treatment, hematopoietic stem cell transplantation, and the incorporation of novel therapeutic agents-as well as protocols for long-term follow-up. The overarching objective is to promote standardized clinical management and ultimately enhance both survival outcomes and quality of life for patients diagnosed with PCL.